Want to see HROW full AI Analyst Report?
HROW Stock Chart & Stats
$41.50
-$0.36(-1.00%)
At close: 4:00 PM EST
$41.50
-$0.36(-1.00%)
Day’s Range― - ―
52-Week Range$28.54 - $54.85
Previous CloseN/A
Volume51.77K
Average Volume (3M)745.77K
Market Cap
$1.74B
Enterprise Value$1.52K
Total Cash (Recent Filing)$94.64M
Total Debt (Recent Filing)$300.67M
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Aug 11, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding37,275,110
10 Day Avg. Volume609,510
30 Day Avg. Volume745,775
Financial Highlights & Ratios
PEG Ratio4.90
Price to Book (P/B)34.35
Price to Sales (P/S)6.61
P/FCF Ratio42.12
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$66.67Price Target Upside60.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.25
Revenue Forecast (FY)$348.36M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Improving Cash FlowSustained ~74–75% gross margins combined with a return to positive operating and free cash flow in 2025 and TTM indicate durable product economics. This cash generation supports reinvestment in commercial expansion and R&D, helping fund growth and reduce reliance on equity issuance over the next several quarters.
Market Share Gains And Durable Product DemandVEVYE's rapid prescription gains and branded share expansion, plus TRIESENCE's sustained multi-quarter unit growth, reflect structural prescriber adoption and a competitive foothold in ophthalmology. Multi-product momentum diversifies revenue drivers and supports multi-month to multi-quarter top-line stability.
Commercial Scale-up And Pipeline/launch CatalystsA meaningful commercial buildout (doubling/tripling reps and adding specialty coverage) increases conversion capacity and supports sustained revenue acceleration. When combined with operational recovery (Access+) and upcoming catalysts (J‑code, distributor stocking, new launches, G‑MELT progress), the company gains durable go‑to‑market leverage.
Bears Say
Very High Leverage And Strained Capital StructureDebt-to-equity rising to roughly 10.5 TTM signals a highly leveraged balance sheet and thin equity cushion. Elevated leverage raises refinancing, interest‑coverage and covenant risks, constraining strategic flexibility and increasing the probability that future growth initiatives depend on costly or dilutive funding over the next several quarters.
Persistent Net Losses Despite Operational ImprovementsAlthough operating profit improved, continuing net losses across reporting periods erode retained earnings and delay attainment of sustainable profitability. Ongoing losses pressure returns on capital and increase the risk the company will need additional financing or strategic cost actions to reach durable net profitability.
Revenue Volatility From Gross-to-net And Channel ShiftsAn $8M one-time gross-to-net hit and channel/inventory dynamics for IHEEZO highlight structural exposure to reimbursement, patient mix and channel transitions. These factors can materially compress realized pricing and create multi‑quarter revenue unpredictability unless commercial rules and payer dynamics are permanently addressed.
Harrow Health News
HROW FAQ
What was Harrow Health’s price range in the past 12 months?
Harrow Health lowest stock price was $28.54 and its highest was $54.85 in the past 12 months.
What is Harrow Health’s market cap?
Harrow Health’s market cap is $1.74B.
When is Harrow Health’s upcoming earnings report date?
Harrow Health’s upcoming earnings report date is Aug 11, 2026 which is in 22 days.
How were Harrow Health’s earnings last quarter?
Harrow Health released its earnings results on May 11, 2026. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.399 by -$0.341.
Is Harrow Health overvalued?
According to Wall Street analysts Harrow Health’s price is currently Undervalued.
Does Harrow Health pay dividends?
Harrow Health does not currently pay dividends.
What is Harrow Health’s EPS estimate?
Harrow Health’s EPS estimate is -0.17.
How many shares outstanding does Harrow Health have?
Harrow Health has 37,275,110 shares outstanding.
What happened to Harrow Health’s price movement after its last earnings report?
Harrow Health reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.399. Following the earnings report the stock price went down -23.686%.
Which hedge fund is a major shareholder of Harrow Health?
Currently, no hedge funds are holding shares in HROW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harrow Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.67 (60.64% Upside)
$66.67 (60.64% Upside)
Blogger Sentiment
Bullish
HROW Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 682.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $468.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.21%
Trailing 12-Months
Company Description
Harrow Health
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
HROW Stock 12 Month Forecast
Average Price Target
$66.67
▲(60.64% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Ownership Overview
20.11% Insiders
9.72% Mutual Funds
0.08% Other Institutional Investors
57.58% Public Companies and Individual Investors